次なる飛躍へ。順調な進捗と共に更なる成長の黎明期にて育ちゆく相場。控える材料と共に水準訂正。笑。
予定されていた業績の急成長と共に更なる成長戦略が始動。順調なR&DやPL等の進捗・拡大の加速。笑。
The scope of the opportunity using the Heptares approach extends well beyond our growing Pipeline.
・・・
※Pluristem News: Pluristem and Sosei CVC Advancing Towards Finalizing Joint Venture for the Commercialization of PLX-PAD in Japan. "Finalized in the coming months." (3/30)
※Heptares Corporate Overview - 2017. Add: "Key Technology Partnerships: Daiichi-Sankyo." (3/31 update)
※ClinicalTrials.gov: A Long-term Safety Study of QVM149 in Japanese Patients with Asthma: (Phase 3, Anticipated Study Start: April 28, 2017) (4/3update)
※Labiotech.eu: Heptares takes home €11M for its clinic-ready Checkpoint Inhibitor. "and were hailed as a major breakthrough." (4/5)
※Parkinson's Approach To Cancer: AACR: CPI-444 had barely any effect. "whose similarly acting AZD4635 showed sufficiently robust preclinical data at AACR." (4/5)
※Drug Profile: Glycopyrrolate/indacaterol: 03 Apr 2017, Launched for COPD in USA (Inhalation) (4/6update)
※米国特許出願: Muscarinic Receptor Agonists (4/6公開)
※BRUKER Products: D8 VENTURE METALJET - Application Note. "in concert with the Heptares StaR technology" (4/7up)
※Innovate UK: Transactions Over £25,000 - February 2017, Grant Expense: Heptares (Amounts: £57,802.28, £74,668.21, £81,261.17) (4/10update)
※Drug Profile AZD4635: 05 Apr 2017, Heptares Completes a Preclinical Study in Cancer. (4/10update)
※ClinicalTrials.gov: Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma. (4/10update)
※Deals Profile: R&D agreement - 29 Jun 2016, Heptares Therapeutics, leadXpro. "In January 2017, This will accelerate the drug discovery efforts." (4/13update)
※Heptares Publications update: Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment.
※DDN-News-4/17: A pair of GPCR deals. The Daiichi Sankyo deal came just over a month after Heptares shared news of another research collaboration with the University of Cambridge. (4/14 up)
※Heptares: Research Scientist in Molecular Pharmacology. "new drug target validation and supporting all drug discovery phases up to PCC selection." (4/13 Recruiting End)
※HeptaresTL: We are currently seeking an experienced molecular biologist to join our protein engineering group GPCR.. "Closing 5/17" (4/18)
※Executive Shifts at Pluristem Therapeutics. (4/18)
Yaky Yanay told OTW,
In the coming months, we intend to execute our clinical program through the expedited regulatory pathways in the U.S., Europe and Japan.
This will include progressing in talks aimed at launching a joint venture with the Sosei Group, initiating the 75-patient pivotal clinical trial using PLX-PAD for CLI [critical limb ischemia] in Japan,
and recruiting patients for our pivotal CLI trials in the U.S. and Europe.
※ClinicalTrials.gov: A Phase 1 Clinical Study of AZD4635 and Durvalumab in Patients With Advanced Solid Malignancies. (4/19update)
※欧州特許: Orexin Receptor Antagonists (4/19公開)
※Pluristem News: Pluristem Reaches Milestone of 100 Granted Patents, Including Coverage of Leading Indications in Major Markets. (4/19)
※BIA - Patient Capital Review, Dr Fiona Marshall: "start-up capital is well funded in the UK, companies are struggling with later-stage fundraisers." (4/20)
※Fund Strategy: Patient capital review: "Heptares as other high profile British businesses that were sold to foreign buyers." (4/20)
※"Mini-G proteins: Novel tools for studying GPCRs in their active conformation": Byron Carpenter (Postdoc, Grant from Heptares), Christopher G. Tate. (4/20)
・・・
※Heptares: We are seeking an Analytical Scientist. "Experience of state-of-the-art automated reverse phase hplc analytical" (Closing 4/25)
・・・
Event:
※Novartis First Quarter Results 2017: 4/25.
※SOSEI 2017年(平成29年)3月期 決算発表：5/12(金)
※SOSEI 個人投資家様向け会社説明会：5/19(金)10:00～13:20
・・・
躍進成長、R&D等の拡充・進捗や中長期成長戦略も着実に進み、次なる展開・進捗が楽しみですね。笑。
***
次なる飛躍へ。順調な進捗と共に更なる成長の黎明期にて育ちゆく相場。控える材料と共に水準訂正。笑。
予定されていた業績の急成長と共に更なる成長戦略が始動。順調なR&DやPL等の進捗・拡大の加速。笑。
The scope of the opportunity using the Heptares approach extends well beyond our growing Pipeline.
・・・
※Pluristem News: Pluristem and Sosei CVC Advancing Towards Finalizing Joint Venture for the Commercialization of PLX-PAD in Japan. "Finalized in the coming months." (3/30)
※Heptares Corporate Overview - 2017. Add: "Key Technology Partnerships: Daiichi-Sankyo." (3/31 update)
※ClinicalTrials.gov: A Long-term Safety Study of QVM149 in Japanese Patients with Asthma: (Phase 3, Anticipated Study Start: April 28, 2017) (4/3update)
※Labiotech.eu: Heptares takes home €11M for its clinic-ready Checkpoint Inhibitor. "and were hailed as a major breakthrough." (4/5)
※Parkinson's Approach To Cancer: AACR: CPI-444 had barely any effect. "whose similarly acting AZD4635 showed sufficiently robust preclinical data at AACR." (4/5)
※Drug Profile: Glycopyrrolate/indacaterol: 03 Apr 2017, Launched for COPD in USA (Inhalation) (4/6update)
※米国特許出願: Muscarinic Receptor Agonists (4/6公開)
※BRUKER Products: D8 VENTURE METALJET - Application Note. "in concert with the Heptares StaR technology" (4/7up)
※Innovate UK: Transactions Over £25,000 - February 2017, Grant Expense: Heptares (Amounts: £57,802.28, £74,668.21, £81,261.17) (4/10update)
※Drug Profile AZD4635: 05 Apr 2017, Heptares Completes a Preclinical Study in Cancer. (4/10update)
※ClinicalTrials.gov: Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma. (4/10update)
※Deals Profile: R&D agreement - 29 Jun 2016, Heptares Therapeutics, leadXpro. "In January 2017, This will accelerate the drug discovery efforts." (4/13update)
※Heptares Publications update: Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment.
※DDN-News-4/17: A pair of GPCR deals. The Daiichi Sankyo deal came just over a month after Heptares shared news of another research collaboration with the University of Cambridge. (4/14 up)
※Heptares: Research Scientist in Molecular Pharmacology. "new drug target validation and supporting all drug discovery phases up to PCC selection." (4/13 Recruiting End)
※HeptaresTL: We are currently seeking an experienced molecular biologist to join our protein engineering group GPCR.. "Closing 5/17" (4/18)
※Executive Shifts at Pluristem Therapeutics. (4/18)
Yaky Yanay told OTW,
In the coming months, we intend to execute our clinical program through the expedited regulatory pathways in the U.S., Europe and Japan.
This will include progressing in talks aimed at launching a joint venture with the Sosei Group, initiating the 75-patient pivotal clinical trial using PLX-PAD for CLI [critical limb ischemia] in Japan,
and recruiting patients for our pivotal CLI trials in the U.S. and Europe.
※ClinicalTrials.gov: A Phase 1 Clinical Study of AZD4635 and Durvalumab in Patients With Advanced Solid Malignancies. (4/19update)
※欧州特許: Orexin Receptor Antagonists (4/19公開)
※Pluristem News: Pluristem Reaches Milestone of 100 Granted Patents, Including Coverage of Leading Indications in Major Markets. (4/19)
※BIA - Patient Capital Review, Dr Fiona Marshall: "start-up capital is well funded in the UK, companies are struggling with later-stage fundraisers." (4/20)
※Fund Strategy: Patient capital review: "Heptares as other high profile British businesses that were sold to foreign buyers." (4/20)
※"Mini-G proteins: Novel tools for studying GPCRs in their active conformation": Byron Carpenter (Postdoc, Grant from Heptares), Christopher G. Tate. (4/20)
・・・
※Heptares: We are seeking an Analytical Scientist. "Experience of state-of-the-art automated reverse phase hplc analytical" (Closing 4/25)
・・・
Event:
※Novartis First Quarter Results 2017: 4/25.
※SOSEI 2017年(平成29年)3月期 決算発表：5/12(金)
※SOSEI 個人投資家様向け会社説明会：5/19(金)10:00～13:20
・・・
躍進成長、R&D等の拡充・進捗や中長期成長戦略も着実に進み、次なる展開・進捗が楽しみですね。笑。